Search for: "JOHN DOE-1"
Results 8821 - 8840
of 14,288
Sort by Relevance
|
Sort by Date
8 May 2012, 5:15 pm
§ 362(d)(1). [read post]
8 May 2012, 9:35 am
UPDATE: A few follow-up thoughts: 1. [read post]
8 May 2012, 9:17 am
[1] 343 U.S. 579 (1952). [read post]
8 May 2012, 8:43 am
John Ramsey, Rosetta Stone Ltd. [read post]
8 May 2012, 6:45 am
John Kerry, with his thinly disguised sympathies for many things French, is Triple Sec’s man in Washington. [read post]
8 May 2012, 5:46 am
Today TaxMama® hears from John in the TaxQuips Forum with a little problem. [read post]
7 May 2012, 8:48 pm
This session’s S1565 does not contain such a provision. [read post]
7 May 2012, 8:26 pm
John Parish, St. [read post]
7 May 2012, 1:13 pm
(John Hudson. [read post]
7 May 2012, 12:06 pm
Occupy, Occupy Wall Street, 99%, 1%: 47 TM applications for Occupy [X] in the past year, 11 for 99%/1%. [read post]
7 May 2012, 11:59 am
Does 1–3757, 2011 U.S. [read post]
7 May 2012, 8:52 am
When a nation does sign a treaty, its obligations are rarely permanent. [read post]
7 May 2012, 8:44 am
The biggest points of disagreement seem to be: 1. [read post]
4 May 2012, 10:23 am
Academy, Golden Globe and Grammy Award-nominee John C. [read post]
4 May 2012, 2:59 am
"I believe the most significant contributing factor is that FDA is part of HHS (Health and Human Services) and does not have the independent ability to bring its own enforcement actions in federal court," explains Kitchens. [read post]
3 May 2012, 2:28 pm
Mr Justice Eder ruled that the injunction would not breach Addison Lee Chairman John Griffin’s free expression rights. [read post]
2 May 2012, 4:44 pm
I don’t think today’s Ninth Circuit decision throwing out Jose Padilla’s damages suit against John Yoo is particularly surprising—notwithstanding the typical (albeit utterly and alarmingly inaccurate) trope about the liberal Ninth Circuit. [read post]
2 May 2012, 2:37 pm
John G. [read post]
2 May 2012, 8:53 am
IOM concludes, “the FDA’s current approach to drug oversight in the postmarket setting is not sufficiently systematic and does not ensure that it assesses the benefits and risks of drugs consistently over the drug’s life cycle. [read post]
2 May 2012, 8:53 am
IOM concludes, “the FDA’s current approach to drug oversight in the postmarket setting is not sufficiently systematic and does not ensure that it assesses the benefits and risks of drugs consistently over the drug’s life cycle. [read post]
